TAK Overview
Upcoming Projects (TAK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TAK)
-
Looking into the phase 3 FRESCO-2 clinical trial data on fruquintinib in patients with refractory metastatic colorectal cancer.
Ticker: TAK
Executed On: Jul 20, 2023 at 03:15 PM EDT -
Examining the potential of Takeda's enzyme replacement therapy, TAK-755 in treating congenital thrombotic thrombocytopenic purpura (cTTP)
Ticker: TAK
Executed On: Jan 24, 2023 at 01:00 PM EST -
Discussing the potential of Takeda's Dengue Vaccine candidate, QDENGA, and Valneva SE's single-shot Chikungunya Vaccine candidate, VLA1553
Tickers: TAK, VALN
Executed On: Dec 21, 2022 at 02:45 PM EST -
A Second Perspective: Discussing a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Tickers: MORF, PTGX, TAK
Executed On: Feb 04, 2022 at 11:00 AM EST -
A discussion around a4b7 integrin blocking in moderate to severe ulcerative colitis: Looking at 1st gen PTG-100 and MORF-057
Tickers: MORF, PTGX, TAK
Executed On: Feb 01, 2022 at 02:00 PM EST -
A Second Look: What's the potential of NMTR's Vurolenatide in short bowel syndrome?
Tickers: NMTR, TAK
Executed On: Jan 06, 2022 at 01:30 PM EST
Upcoming & Overdue Catalysts (TAK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (TAK)
Strategic Initiatives (TAK)
-
Takeda Pharmaceutical Co(TAK) to sell eye drug Xiidra to Novartis AG(NVS)
Tickers: NVS, TAK
Announcement Date: May 08, 2019
